Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells
Byung Chul Jung1,2, Sung-Hun Woo2, Sung Hoon Kim3,4
1Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, U.S.A.
Background/Aim:
Gefitinib exhibits anticancer activity against cervical cancer cells via anoikis, a type of apoptosis induced by cell detachment from the extracellular matrix. Previous studies have reported that Parkin expression affects the efficacy of anticancer drugs. However, the impact of Parkin expression on the therapeutic effects of gefitinib in human cervical cancer remains unclear. Thus, this study aimed to evaluate whether Parkin over-expression improves the therapeutic effects of gefitinib against HeLa cervical cancer cells.
Materials And Methods:
Cell viability and apoptotic death of HeLa cells were measured by trypan blue dye exclusion assay and flow cytometry. Cell detachment, adhesion, spreading, and cell-cell interaction were observed by inverted microscopy. Alteration of adhesion-related molecules was evaluated by confocal microscopy and western blot assay.
Results:
Parkin expression potentiated gefitinib-induced cell detachment by affecting the organization of the actin cytoskeleton. In addition, Parkin expression induced a further reduction in the reattachment of and interaction between detached cells. The therapeutic efficacy of low-dose gefitinib combined with Parkin expression was equivalent to that of high-dose gefitinib alone.
Conclusion:
Parkin expression promotes gefitinib-induced anoikis, consequently increasing the efficacy of gefitinib against HeLa human cervical cancer cells. Based on our results, we propose that Parkin can be used to increase the anti-cancer effect of gefitinib on cervical cancer cells.
Insights
Parkin expression enhances gefitinib
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Gefitinib shows anticancer effects in cervical cancer through anoikis.
- Parkin protein's role in anticancer drug efficacy is known but its impact on gefitinib in cervical cancer is unclear.
Purpose of the Study:
- To investigate if Parkin overexpression enhances gefitinib's therapeutic effects on HeLa cervical cancer cells.
- To explore the mechanism of Parkin's influence on gefitinib-induced anoikis.
Main Methods:
- HeLa cell viability and apoptosis assessed via trypan blue assay and flow cytometry.
- Cell detachment, adhesion, and spreading observed using microscopy.
- Adhesion molecule changes analyzed by confocal microscopy and Western blot.
Main Results:
- Parkin expression amplified gefitinib-induced cell detachment by altering actin cytoskeleton organization.
- Parkin reduced reattachment and interaction of detached cells.
- Low-dose gefitinib with Parkin matched high-dose gefitinib efficacy.
Conclusions:
- Parkin expression promotes gefitinib-induced anoikis, enhancing its efficacy against cervical cancer.
- Parkin may serve as a strategy to boost gefitinib's anti-cancer activity in cervical cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:38Mitogens and the Cell Cycle